Thomas Helleday - Selected Publications#

1. Bryant, H.E., Schultz, N, Thomas, H.D., Parker, K.M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N.J., Helleday, T#. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)polymerase Nature, 434, 913-7.

2. Sørensen, C.S., Hansen, L.T., Dziegielewski, J., Syljuåsen, R.G., Lundin, C., Bartek, J.#, Helleday, T.#. (2005) The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair, Nature Cell Biology, 7(2), 195-201. (# co-correspondent authors)

3. Petermann E, Orta L, Issaeva N, Schultz N and Helleday T#. (2010) Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51- mediated pathways for restart and repair, Molecular Cell, 37, 492-502.

4. Gad H, Koolmeister T, Jemth A-S,... 48 authors..., Scobie M, Warpman Berglund U, Helleday T#. (2014) MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 508(7495):215-21.

5. Visnes, T., Cázares-Körner, A., Hao, W., Wallner, O., Masuyer, G., Loseva, O., Mortusewicz O., Wiita, E., Sarno, A., Manoilov, A., Astorga-Wells, J., Jemth, A.S., Pan, L., Sanjiv, K., Karsten, S., Gokturk, C., Grube, M., Homan, E.J., Hanna, B.M.F., Paulin, C.B.J., Pham, T., Rasti, A., Berglund, U.W., von Nicolai, C., Benitez-Buelga, C., Koolmeister, T., Ivanic, D., Iliev, P., Scobie, M., Krokan, H.E., Baranczewski, P., Artursson, P., Altun, M., Jensen, A.J., Kalderén, C., Ba, X., Zubarev, R.A., Stenmark, P., Boldogh, I. #, Helleday, T#.(2018) Small-molecule inhibitor of OGG1 suppresses proinflammatory gene expression and inflammation. Science, 16;362(6416):834-839. (# co-correspondent authors)

6. Tarish FL, Schultz N, Tanoglidi A, Hamberg H, Letocha H, Karaszi K, Hamdy FC, Granfors T, Helleday T#. (2015) Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair. Science Translational Medicine. 7(312):312re11.

7. Zhang SM, Desroses M, Hagenkort A, Valerie NCK, Rehling D, Carter M, Wallner O, Koolmeister T, Throup A, Jemth AS, Almlöf I, Loseva O, Lundbäck T, Axelsson H, Regmi S, Sarno A, Krämer A, Pudelko L, Bräutigam L, Rasti A, Göttmann M, Wiita E, Kutzner J, Schaller T, Kalderén C, Cázares-Körner A, Page BDG, Krimpenfort R, Eshtad S, Altun M, Rudd SG, Knapp S, Scobie M, Homan EJ, Berglund UW, Stenmark P, Helleday T#. (2020) Development of a chemical probe against NUDT15. Nature Chemical Biology. 16(10):1120-1128.

8. Moskwa P, Buffa FM, Pan Y, Panchakshari R, Vischioni B, Parker A, Pezzella F, Gottipati P, Abdelmohsen K, Camps C, Ragoussis J, Kulshrestha R, Weinstock DM, Sharma RA, Gorospe M, Harris AL, Helleday T# and Chowdhury D#. (2011). miR-182-mediated down-regulation of BRCA1 impacts on the DNA damage response and breast cancer therapy. Molecular Cell, 41:210-20. (# co-correspondent authors)

9. Page BDG#, Valerie NCK, Wright RHG, Wallner O, Isaksson R, Carter M, Rudd SG, Loseva O, Jemth AS, Almlöf I, Font-Mateu J, Llona-Minguez S, Baranczewski P, Jeppsson F, Homan E, Almqvist H, Axelsson H, Regmi S, Gustavsson AL, Lundbäck T, Scobie M, Strömberg K, Stenmark P, Beato M, Helleday T#. (2018) Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells. Nature Communications. 9(1):250.

10. Xie S, Mortusewicz O, Ma HT, Herr P, Poon RR, Helleday T#, Qian C#. (2015). Timeless Interacts with PARP-1 to Promote Homologous Recombination Repair. Molecular Cell. 60(1):163-76. (# co-correspondent authors)